These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38250137)

  • 61. Dupilumab improves health-related quality of life in patients with chronic rhinosinusitis with nasal polyposis.
    Bachert C; Hellings PW; Mullol J; Hamilos DL; Gevaert P; Naclerio RM; Joish VN; Chao J; Mannent LP; Amin N; Abbe A; Taniou C; Fan C; Pirozzi G; Graham NMH; Mahajan P; Staudinger H; Khan A
    Allergy; 2020 Jan; 75(1):148-157. PubMed ID: 31306495
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The Effect of Dupilumab on Intractable Chronic Rhinosinusitis with Nasal Polyps in Japan.
    Fujieda S; Matsune S; Takeno S; Asako M; Takeuchi M; Fujita H; Takahashi Y; Amin N; Deniz Y; Rowe P; Mannent L
    Laryngoscope; 2021 Jun; 131(6):E1770-E1777. PubMed ID: 33226139
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Rapid effect of benralizumab for severe asthma with chronic rhinosinusitis with nasal polyps.
    Matsuno O; Minamoto S
    Pulm Pharmacol Ther; 2020 Oct; 64():101965. PubMed ID: 33039667
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Dupilumab Efficacy in Patients With Uncontrolled or Oral Corticosteroid-Dependent Allergic and Nonallergic Asthma.
    Brusselle G; Quirce S; Papi A; Kuna P; Chipps BE; Hanania NA; Blaiss M; Msihid J; Jacob-Nara JA; Deniz Y; Rowe PJ; Gall R; Ortiz B; Djandji M; Radwan A
    J Allergy Clin Immunol Pract; 2023 Mar; 11(3):873-884.e11. PubMed ID: 36572184
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Biologics for chronic rhinosinusitis.
    Chong LY; Piromchai P; Sharp S; Snidvongs K; Philpott C; Hopkins C; Burton MJ
    Cochrane Database Syst Rev; 2020 Feb; 2(2):CD013513. PubMed ID: 32102112
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Health-Related Quality of Life Impairment Among Patients with Severe Chronic Rhinosinusitis with Nasal Polyps in the SINUS-24 Trial.
    Maspero JF; Khan AH; Philpott C; Hellings PW; Hopkins C; Wagenmann M; Siddiqui S; Msihid J; Nash S; Chuang CC; Kamat S; Rowe PJ; Deniz Y; Jacob-Nara JA
    J Asthma Allergy; 2023; 16():323-332. PubMed ID: 37016622
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Dupilumab Efficacy in Uncontrolled, Moderate-to-Severe Asthma with Self-Reported Chronic Rhinosinusitis.
    Maspero JF; Katelaris CH; Busse WW; Castro M; Corren J; Chipps BE; Peters AT; Pavord ID; Ford LB; Sher L; Rabe KF; Rice MS; Rowe P; Lu Y; Harel S; Jagerschmidt A; Khan AH; Kamat S; Pirozzi G; Amin N; Ruddy M; Graham NMH; Mannent LP; Teper A
    J Allergy Clin Immunol Pract; 2020 Feb; 8(2):527-539.e9. PubMed ID: 31351189
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Impact of sinus surgery on type 2 airway and systemic inflammation in asthma.
    Hamada K; Oishi K; Chikumoto A; Murakawa K; Ohteru Y; Matsuda K; Uehara S; Suetake R; Ohata S; Murata Y; Yamaji Y; Asami-Noyama M; Ito K; Edakuni N; Hirano T; Matsunaga K
    J Asthma; 2021 Jun; 58(6):750-758. PubMed ID: 32050820
    [No Abstract]   [Full Text] [Related]  

  • 69. Cost-Utility Analysis of Dupilumab for the Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Italy.
    De Corso E; Furneri G; Salsi D; Fanelli F; Ronci G; Sala G; Bitonti R; Cuda D
    J Pers Med; 2022 Jun; 12(6):. PubMed ID: 35743736
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic Asthma.
    Corren J; Castro M; O'Riordan T; Hanania NA; Pavord ID; Quirce S; Chipps BE; Wenzel SE; Thangavelu K; Rice MS; Harel S; Jagerschmidt A; Khan AH; Kamat S; Maroni J; Rowe P; Lu Y; Amin N; Pirozzi G; Ruddy M; Graham NMH; Teper A
    J Allergy Clin Immunol Pract; 2020 Feb; 8(2):516-526. PubMed ID: 31521831
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma.
    Busse WW; Maspero JF; Rabe KF; Papi A; Wenzel SE; Ford LB; Pavord ID; Zhang B; Staudinger H; Pirozzi G; Amin N; Akinlade B; Eckert L; Chao J; Graham NMH; Teper A
    Adv Ther; 2018 May; 35(5):737-748. PubMed ID: 29725983
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Cost Utility Analysis of Dupilumab Versus Endoscopic Sinus Surgery for Chronic Rhinosinusitis With Nasal Polyps.
    Scangas GA; Wu AW; Ting JY; Metson R; Walgama E; Shrime MG; Higgins TS
    Laryngoscope; 2021 Jan; 131(1):E26-E33. PubMed ID: 32243622
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Dupilumab efficacy in high sleep disturbance management among patients with type 2 asthma.
    Maspero JF; Shafazand S; Cole J; Pavord ID; Busse WW; Msihid J; Gall R; Soler X; Radwan A; Khan AH; de Prado Gómez L; Jacob-Nara JA
    Respir Med; 2023 Nov; 218():107344. PubMed ID: 37659435
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Nasal Brushing Molecular Endotyping Distinguishes CRSwNP Patients with Better Response to Dupilumab.
    Gayvert K; Desrosiers M; Laidlaw TM; Mannent LP; Patel K; Horowitz J; Amin N; Jagerschmidt A; Hamilton JD; Lim WK; Harel S
    J Allergy Clin Immunol; 2024 Jun; ():. PubMed ID: 38880251
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Dupilumab in chronic rhinosinusitis with nasal polyposis: current status, challenges, and future perspectives.
    Li T; Yin J; Yang Y; Wang G; Zhang Y; Song X
    Expert Rev Clin Immunol; 2023; 19(8):939-948. PubMed ID: 37378551
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Two-year results of tapered dupilumab for CRSwNP demonstrates enduring efficacy established in the first 6 months.
    van der Lans RJL; Otten JJ; Adriaensen GFJPM; Hoven DR; Benoist LB; Fokkens WJ; Reitsma S
    Allergy; 2023 Oct; 78(10):2684-2697. PubMed ID: 37394895
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial.
    Bachert C; Han JK; Desrosiers MY; Gevaert P; Heffler E; Hopkins C; Tversky JR; Barker P; Cohen D; Emson C; Martin UJ; Shih VH; Necander S; Kreindler JL; Jison M; Werkström V
    J Allergy Clin Immunol; 2022 Apr; 149(4):1309-1317.e12. PubMed ID: 34599979
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Dupilumab in CRSwNP: Responder Analysis Using Clinically Meaningful Efficacy Outcome Thresholds.
    Chuang CC; Guillemin I; Bachert C; Lee SE; Hellings PW; Fokkens WJ; Duverger N; Fan C; Daizadeh N; Amin N; Mannent LP; Khan AH; Kamat S
    Laryngoscope; 2022 Feb; 132(2):259-264. PubMed ID: 34817082
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Dupilumab Efficacy in Patients with Type 2 Asthma with and without Elevated Blood Neutrophils.
    Bleecker ER; Panettieri RA; Lugogo NL; Corren J; Daizadeh N; Jacob-Nara JA; Deniz Y; Rowe PJ; Khodzhayev A; Soler X; Ferro TJ; Hansen CN
    J Immunol Res; 2023; 2023():9943584. PubMed ID: 37901346
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Eosinophil Cationic Protein Variation in Patients with Asthma and CRSwNP Treated with Dupilumab.
    Ledda AG; Costanzo G; Sambugaro G; Caruso C; Bullita M; Di Martino ML; Serra P; Firinu D; Del Giacco S
    Life (Basel); 2023 Sep; 13(9):. PubMed ID: 37763288
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.